The So What, Who Cares (SW2C) Test

Even as early as seed level, companies need to answer two questions that can determine whether an investor will invest

Investors will always ask about the science, the feasibility, its approvability and the regulatory pathway. But increasingly, in today’s conservative investment environment, they’re about the commercial viability of the product the company is developing.

They’ve learned the hard way that a company can have compelling clinical data, a validated mechanism, and a disease area with genuine suffering. Those are table stakes. None of that guarantees the product will actually be used and that’s what drives exits for investors..

The real commercial test — the one that separates funded hope from enterprise value — is whether the product solves a meaningful problem well enough to overcome the friction of changing behavior across an entire healthcare system.

That test comes down to two blunt questions:

and

These aren't rhetorical. They're diagnostic. And companies need to be able to answer them sufficiently to de-risk the investment for the investor.

"So what?" is not really a question about unmet need

Every market has unmet need. Investors know this. What they don't know — and what most companies fail to make clear — is whether the product being developed is incremental, meaningful, or transformational.

The right version of this question isn't: Is there currently room for improvement in the treatment of this disease?

It's: What’s not working currently, how does this product improve the current treatment algorithm, and what outcomes does it deliver?

The answer needs to be as specific as possible: better efficacy, greater safety, lower cost… The improvement has to be large enough to be able to make a meaningful difference in a physician’s practice or a patient’s lifestyle.

"Who cares?" is not a question about market size

Healthcare adoption is rarely driven by one decision maker. Depending on the product, there’s an ecosystem of physicians, patients, payers, health systems, specialty pharmacies, guideline committees, care teams, and employers.

The question has become less whether the product is seen as novel and valuable than whether someone who really advocates for this product and its adoption will have enough motivation and influence to align the other stakeholders and drive its adoption.

Almost equally important: who has enough to lose — financially, operationally, professionally —if the product is

not adopted?

This is where superior science often falls short. Companies assume better efficacy drives adoption. In today’s healthcare ecosystem, adoption is a behavioral and organizational phenomenon, not a purely scientific one.

The traditional TPP is focused on approval, not adoption

The Target Product Profile is usually designed to answer regulatory and clinical positioning questions. It tells you what the label might say. It doesn't tell you whether physicians will switch, whether payers will reimburse without a fight, or whether a health system can operationalize the therapy without significant workflow disruption. And I’ve yet to see a TPP built around the patient and what endpoints or outcomes will motivate them to accelerate a visit to their physician. As the GLP-1s have demonstrated, patients are willing to push for getting access to new medications if the benefits to them clinically are clear.

Identifying future commercial success requires a second layer of diligence — one that not only maps to clinical superiority but also encompasses the hidden friction in the adoption pathway before a company has committed to a development program built around the wrong assumptions.

The RAMPx (Realistic Assessment of Market Potential) model helps address the So-What, Who Cares Questions

The RAMPx framework was built to quantify the forces that accelerate or resist adoption once a product reaches the market. RAMPx doesn't ask whether a product is differentiated. It asks whether it's adoptable. Those are different questions, and confusing them is expensive.

What RAMPx evaluates:

• How much better is the new product vs the standard of care?

• How easy is the new product to adopt in terms of workflow, operational complexity, and lifestyle?

• What is the perceived risk at the prescriber level of being an early adopter, that a patient may feel about being an early adopter, or for someone who’s receiving a relatively new therapy?

The RAMPx Score measures these three drivers of new product adoption across 12 factors and provides a more realistic view of how readily a new product will be adopted and it measures this by each stakeholder. RAMPx can be implemented very early and affordably for startups. Most importantly, it validates the future commercial potential of the new product you’re developing and de-risks the opportunity for prospective investors.

The investor insight this unlocks

Even early investors are starting to look beyond the product toward future commercialization and likely adoption. Will the product drive future prescribing behavior, future payer acceptance, future operational scalability?

The commercial winners in biotech are not always the products with the best science. They are the products with adequate differentiation, compelling usability, lower implementation friction, and a clearer path through a system that was not designed to adopt new things easily.

Understanding that gap — between scientific possibility and commercial adoption — early enough to do something about it is the discipline that RAMPx is built to enable.